StreetInsider.com News Articles

UBS Assumes Pacific Biosciences of California (PACB) at Neutral

Wed, 09 Sep 2026 06:08:10 -0400

UBS analyst Douglas Schenkel assumes coverage on Pacific Biosciences of California (NASDAQ: PACB) with a Neutral rating and a price target of $1.35.

For an analyst ratings summary and ratings history on Pacific Biosciences of California click here. For more ratings news on Pacific Biosciences of California click here.

Shares of Pacific Biosciences of California closed at $1.32 yesterday.

Form 4 PACIFIC BIOSCIENCES OF For: Aug 17 Filed by: Van Oene Mark

Tue, 18 Aug 2026 20:17:00 -0400

si-local-file:///var/storage/secattach/20260818/26945993.html

Form 4 PACIFIC BIOSCIENCES OF For: Aug 17 Filed by: Van Oene Mark

Tue, 18 Aug 2026 20:17:00 -0400

si-local-file:///var/storage/secattach/20260818/26945993.html

Form 144 PACIFIC BIOSCIENCES OF Filed by: Van Oene Mark

Mon, 17 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260817/26938018.html

Form 144 PACIFIC BIOSCIENCES OF Filed by: Van Oene Mark

Mon, 17 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260817/26938018.html

Form SCHEDULE 13G/A PACIFIC BIOSCIENCES OF Filed by: ARK Investment Management LLC

Fri, 14 Aug 2026 14:53:00 -0400

si-local-file:///var/storage/secattach/20260814/26929222.html

Form SCHEDULE 13G/A PACIFIC BIOSCIENCES OF Filed by: ARK Investment Management LLC

Fri, 14 Aug 2026 14:53:00 -0400

si-local-file:///var/storage/secattach/20260814/26929222.html

Form 4 PACIFIC BIOSCIENCES OF For: Aug 10 Filed by: Van Oene Mark

Tue, 11 Aug 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20260811/26907322.html

Form 4 PACIFIC BIOSCIENCES OF For: Aug 10 Filed by: Van Oene Mark

Tue, 11 Aug 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20260811/26907322.html

Form S-8 PACIFIC BIOSCIENCES OF

Fri, 07 Aug 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260807/26886965.html

Form S-8 PACIFIC BIOSCIENCES OF

Fri, 07 Aug 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260807/26886965.html

Form 10-Q PACIFIC BIOSCIENCES OF For: Jun 30

Thu, 06 Aug 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26885729.html

Form 10-Q PACIFIC BIOSCIENCES OF For: Jun 30

Thu, 06 Aug 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26885729.html

Pacific Bio (PACB) Misses Q2 EPS by 1c

Wed, 05 Aug 2026 16:26:18 -0400

Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $39 million versus the consensus estimate of $40.69 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

Form 8-K PACIFIC BIOSCIENCES OF For: Jul 30

Wed, 05 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260805/26874852.html

Form 8-K PACIFIC BIOSCIENCES OF For: Jul 30

Wed, 05 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260805/26874852.html

PacBio names Mark Van Oene as CEO, replacing Christian Henry

Wed, 05 Aug 2026 16:08:11 -0400

Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced that its Board of Directors has appointed Mark Van Oene as President and Chief Executive Officer, effective Aug. 5, 2026.

Van Oene, who previously served as the company's Chief Operating Officer since joining PacBio in 2021, succeeds Christian Henry, who stepped down after six years in the role. Van Oene has also been appointed to PacBio's Board of Directors.

Henry will remain on the Board of Directors and has agreed to serve as a business advisor to the company through at least the end of 2026 to support the transition.

John Milligan, Ph.D., Chair of

PacBio names Mark Van Oene as CEO, replacing Christian Henry

Wed, 05 Aug 2026 16:08:11 -0400

Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced that its Board of Directors has appointed Mark Van Oene as President and Chief Executive Officer, effective Aug. 5, 2026.

Henry will remain on the Board of Directors and has agreed to serve as a business advisor to the company through at least the end of 2026 to support the transition.

John Milligan, Ph.D., Chair of

PacBio Appoints Mark Van Oene as President and Chief Executive Officer

Wed, 05 Aug 2026 16:08:00 -0400

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions, today announced that its Board of Directors has appointed Mark Van Oene as President and Chief Executive Officer, effective August 5, 2026. Mr. Van Oene, who has served as Chief Operating Officer, succeeds Christian Henry, who has stepped down as President and Chief Executive Officer after six years leading PacBio. Mr. Van Oene has also been appointed to serve on PacBio's Board of Directors, effective August 5, 2026. Mr. Henry will continue

PacBio Appoints Mark Van Oene as President and Chief Executive Officer

Wed, 05 Aug 2026 16:08:00 -0400

PacBio Appoints Mark Van Oene as President and Chief Executive Officer

Wed, 05 Aug 2026 16:08:00 -0400

PacBio Appoints Mark Van Oene as President and Chief Executive Officer

Wed, 05 Aug 2026 16:08:00 -0400

PacBio Announces Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026.

Recent Business Highlights

Total revenue of $39.0 million was driven by growing consumables and new Revio and Vega placements as the Company commenced its full rollout of SPRQ-Nx chemistry. Instrument revenue consisted of both single-system and multi-system orders, including an order for several Revio systems from a new population-scale customer
Commenced global commercial rollout of SPRQ-Nx, delivering whole genome sequencing at $345 USD list price per genome with enhanced methylation detection

PacBio Announces Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026.

Recent Business Highlights

Total revenue of $39.0 million was driven by growing consumables and new Revio and Vega placements as the Company commenced its full rollout of SPRQ-Nx chemistry. Instrument revenue consisted of both single-system and multi-system orders, including an order for several Revio systems from a new population-scale customer
Commenced global commercial rollout of SPRQ-Nx, delivering whole genome sequencing at $345 USD list price per genome with enhanced methylation detection

PacBio Announces Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026.

Recent Business Highlights

Total revenue of $39.0 million was driven by growing consumables and new Revio and Vega placements as the Company commenced its full rollout of SPRQ-Nx chemistry. Instrument revenue consisted of both single-system and multi-system orders, including an order for several Revio systems from a new population-scale customer
Commenced global commercial rollout of SPRQ-Nx, delivering whole genome sequencing at $345 USD list price per genome with enhanced methylation detection